Robert Joseph Volk

Robert Joseph Volk

Auto-generated profile, based on publicly available information

Robert Joseph Volk

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2007 in Alcohol, Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
KBKatharine A. Bradley
Katharine A. Bradley
ADAnna F. DeBenedetti
Anna F. DeBenedetti
RVRobert J. Volk
Robert J. Volk
EWEmily C. Williams
Emily C. Williams
DFDanielle Frank
Danielle Frank
DKDaniel R. Kivlahan
Daniel R. Kivlahan

1 March 2010 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Closed access
AWA. M. D. Wolf
A. M. D. Wolf
RWR. C. Wender
R. C. Wender
RER. B. Etzioni
R. B. Etzioni
ITI. M. Thompson
I. M. Thompson
ADA. V. D'AMico
A. V. D'AMico
RSR. A. Smith
R. A. Smith

20 August 2013 in Medical Decision Making
Verified
Journal Article
Closed access
NJNatalie Joseph-Williams
Natalie Joseph-Williams
RNRobert Newcombe
Robert Newcombe
MPMary Politi
Mary Politi
MDMarie-Anne Durand
Marie-Anne Durand
SSStephanie Sivell
Stephanie Sivell
GEGlyn Elwyn
Glyn Elwyn
Objective. The IPDAS Collaboration has developed a checklist and an instrument (IPDASi v3.0) to assess the quality of patient decision aids (PDAs) in terms of their development process and shared decision-making design components. Certification of PDAs is of growing interest in the US and elsewhere. We report a modified Delphi consensus process to agree on IPDASi (v3.0) items that should be considered as minimum standards for PDA certification, for inclusion in the refined IPDASi (v4.0). Methods. A 2-stage Delphi voting process considered the inclusion of IPDASi (v3.0) items as minimum standards. Item scores and qualitative comments were analyzed, followed by expert group discussion. Results. One hundred and one people voted in round 1; 87 in round 2. Forty-seven items were reduced to 44 items across 3 new categories: 1) qualifying criteria, which are required in order for an intervention to be considered a decision aid (6 items); 2) certification criteria, without which a decision aid is judged to have a high risk of harmful bias (10 items); and 3) quality criteria, believed to strengthen a decision aid but whose omission does not present a high risk of harmful bias (28 items). Conclusions. This study provides preliminary certification criteria for PDAs. Scoring and rating processes need to be tested and finalized. However, the process of appraising the quality of the clinical evidence reported by the PDA should be used to complement these criteria; the proposed standards are designed to rate the quality of the development process and shared decision-making design elements, not the quality of the PDA’s clinical content.

18 April 2008 in Journal of General Internal Medicine
Verified
Journal Article
Open access
PDF file
DFDanielle Frank
Danielle Frank
ADAnna F. DeBenedetti
Anna F. DeBenedetti
RVRobert J. Volk
Robert J. Volk
EWEmily C. Williams
Emily C. Williams
DKDaniel R. Kivlahan
Daniel R. Kivlahan
KBKatharine A. Bradley
Katharine A. Bradley
The Alcohol Use Disorders Identification Test—Consumption (AUDIT-C) is a brief validated screen for risky drinking and alcohol abuse and dependence (alcohol misuse). However, the AUDIT-C was validated in predominantly White populations, and its performance in different racial/ethnic groups is unclear. To evaluate the validity of the AUDIT-C among primary care patients from the predominant racial/ethnic subgroups within the United States: White, African American, and Hispanic. Cross-sectional interview validation study. 1,292 outpatients from an academic family practice clinic in Texas (90% of randomly sampled eligible). Race/ethnicity was self-reported. Areas under the receiver operating curve (AuROCs) evaluated overall AUDIT-C performance in the 3 racial/ethnic groups compared to diagnostic interviews for alcohol misuse. AUDIT-C sensitivities and specificities at recommended screening thresholds were compared across racial/ethnic groups. AuROCs were greater than 0.85 in all 3 groups, with no significant differences across racial/ethnic groups in men (P = .43) or women (P = .12). At previously recommended cut points, there were statistically significant differences by race in AUDIT-C sensitivities but not specificities. In women, the sensitivity was higher in Hispanic (85%) than in African-American (67%; P = .03) or White (70%; P = .04) women. In men, the sensitivity was higher in White (95%) than in African-American men (76%; P = .01), with no significant difference from Hispanic men (85%; P = .11). The overall performance of the AUDIT-C was excellent in all 3 racial/ethnic groups as reflected by high AuROCs. At recommended cut points, there were significant differences in the AUDIT-C’s sensitivity but not in specificity across the 3 racial/ethnic groups.

19 June 2021 in Medical Decision Making
Verified
Journal Article
Open access
PDF file
HWHolly O. Witteman
Holly O. Witteman
KMKristin G. Maki
Kristin G. Maki
GVGratianne Vaisson
Gratianne Vaisson
JFJeanette Finderup
Jeanette Finderup
KLKrystina B. Lewis
Krystina B. Lewis
RVRobert J. Volk
Robert J. Volk
The 2013 update of the evidence informing the quality dimensions behind the International Patient Decision Aid Standards (IPDAS) offered a model process for developers of patient decision aids. To summarize and update the evidence used to inform the systematic development of patient decision aids from the IPDAS Collaboration. To provide further details about design and development methods, we summarized findings from a subgroup (n = 283 patient decision aid projects) in a recent systematic review of user involvement by Vaisson et al. Using a new measure of user-centeredness (UCD-11), we then rated the degree of user-centeredness reported in 66 articles describing patient decision aid development and citing the 2013 IPDAS update on systematic development. We contacted the 66 articles’ authors to request their self-reports of UCD-11 items. The 283 development processes varied substantially from minimal iteration cycles to more complex processes, with multiple iterations, needs assessments, and extensive involvement of end users. We summarized minimal, medium, and maximal processes from the data. Authors of 54 of 66 articles (82%) provided self-reported UCD-11 ratings. Self-reported scores were significantly higher than reviewer ratings (reviewers: mean [SD] = 6.45 [3.10]; authors: mean [SD] = 9.62 [1.16], P < 0.001). Decision aid developers have embraced principles of user-centered design in the development of patient decision aids while also underreporting aspects of user involvement in publications about their tools. Templates may reduce the need for extensive development, and new approaches for rapid development of aids have been proposed when a more detailed approach is not feasible. We provide empirically derived benchmark processes and a reporting checklist to support developers in more fully describing their development processes.

2 November 2020 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
MLMaria A. Lopez-Olivo
Maria A. Lopez-Olivo
KMKristin G. Maki
Kristin G. Maki
NCNoah J. Choi
Noah J. Choi
RHRichard M. Hoffman
Richard M. Hoffman
YSYa-Chen Tina Shih
Ya-Chen Tina Shih
RVRobert J. Volk
Robert J. Volk
Screening high-risk current and former smokers for lung cancer with low-dose computed tomography (LDCT) reduces deaths from lung cancer.1-3 The US Preventive Services Task Force recommends annual screening with LDCT for individuals with a smoking history of at least 30 pack-years who currently smoke or have quit within the past 15 years, are between 55 and 80 years of age, and meet other eligibility criteria.4 Screening should continue annually until the person is no longer eligible.5